STOCK TITAN

FOXO Technologies Inc. Subsidiary, Big South Fork Medical Center, Expands Clinical Capabilities

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags

FOXO Technologies (OTC: FOXO) said its critical access hospital, Big South Fork Medical Center (Scott County Community Hospital), expanded clinical capabilities on Jan 20, 2026. The hospital added inpatient tele-specialty coverage in cardiology, pulmonology, and nephrology through a partnership with Rural Physicians Group, enabling more specialty evaluation and treatment locally and aiming to reduce patient transfers. The facility also implemented on-site echocardiography services with professional interpretation provided by CompuMed. Management said the additions strengthen local treatment capacity, improve care access, and support a technology-enabled care model intended to help long-term sustainability and increase net revenues.

Loading...
Loading translation...

Positive

  • Inpatient tele-specialty coverage added in cardiology, pulmonology, and nephrology
  • Partnership established with Rural Physicians Group to deliver tele-specialty services
  • On-site echocardiography implemented with interpretation by CompuMed
  • Expected reduction in unnecessary patient transfers due to expanded local care

Negative

  • None.

News Market Reaction

%
1 alert
% News Effect

On the day this news was published, FOXO declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.0001 Vol: Volume 44,788,286 is belo...
low vol
$0.0001 Last Close
Volume Volume 44,788,286 is below the 20-day average of 97,373,271 (relative volume 0.46). low
Technical Price 0.000105 is trading below the 200-day MA of 0.47, indicating a weak longer-term trend.

Peers on Argus

FOXO showed 0% move pre-news while peers were mixed: OTRK -18.89%, BEAT -5.02%, ...

FOXO showed 0% move pre-news while peers were mixed: OTRK -18.89%, BEAT -5.02%, BFRG -6.49%, POAI 0%, WORX +3.01%, suggesting no clear sector-wide pattern tied to this announcement.

Historical Context

5 past events · Latest: Dec 15 (Positive)
Pattern 5 events
Date Event Sentiment Move Catalyst
Dec 15 Year-end review Positive +0.0% 2025 operational growth, higher net revenues, equity improvement, debt reduction.
Dec 09 Subsidiary recognition Positive +0.0% Myrtle Recovery Centers honored for rural community impact and high utilization.
Sep 22 Acquisition closing Positive +12.0% Closing of Vector BioSource deal with defined revenue base and growth funding.
Sep 11 Acquisition agreement Positive -16.9% Agreement to acquire Vector BioSource with cash, preferred stock, and warrants.
Aug 13 Delisting/OTC move Negative -91.8% NYSE American delisting for low price; stock moved to OTC market.
Pattern Detected

Positive corporate and operational updates have often seen muted or negative price reactions, while clearly negative listing-related news aligned with sharp declines.

Recent Company History

Over the last six months, FOXO reported multiple strategic and operational milestones, including acquisitions like Vector BioSource, recognition for Myrtle Recovery Centers, and a detailed year-end 2025 review highlighting higher net revenues and debt reduction. Despite generally constructive operational news, several events showed flat or negative price reactions. In contrast, listing-related developments, including the NYSE American delisting and transition to OTC trading, coincided with a steep negative move. Today’s hospital capability expansion follows this pattern of operational progress against a challenging equity backdrop.

Market Pulse Summary

This announcement centers on expanded inpatient tele-specialty coverage and on-site echocardiography...
Analysis

This announcement centers on expanded inpatient tele-specialty coverage and on-site echocardiography at Big South Fork Medical Center, supporting FOXO’s goal of a technology-enabled rural care model. Recent history shows the company pursuing acquisitions and growing healthcare revenues while managing leverage and complex capital-structure changes disclosed in periodic filings. Investors may focus on how these added services ultimately influence patient volumes, payor mix, and net revenues at the hospital within FOXO’s broader portfolio.

Key Terms

tele-specialty, cardiology, pulmonology, nephrology, +1 more
5 terms
tele-specialty medical
"addition of inpatient tele-specialty services and cardiac diagnostics."
Tele-specialty is the delivery of medical specialist care—such as cardiology, dermatology, or neurology—remotely using video, digital images, and electronic records instead of in-person visits. For investors, it matters because it can lower costs, expand a provider’s reach like turning a local shop into an online store, create new revenue streams and partnerships, and is sensitive to reimbursement rules and technology adoption that affect profitability and growth.
cardiology medical
"tele-specialty coverage in cardiology, pulmonology, and nephrology, enabling"
Cardiology is the medical specialty that diagnoses and treats the heart and blood vessels, ranging from routine checkups to interventions for heart attacks and chronic heart failure. Investors watch cardiology because advances in treatments, devices, tests or guidelines can change demand, costs and regulatory risk for drugmakers, device makers and hospitals — like a car mechanic’s new tool changing which repair shops get business and how much they can charge.
pulmonology medical
"tele-specialty coverage in cardiology, pulmonology, and nephrology, enabling"
Pulmonology is the medical specialty that diagnoses and treats disorders of the lungs and breathing passages, including conditions like asthma, chronic obstructive disease, infections and sleep-related breathing problems. For investors, pulmonology matters because advances in drugs, devices or diagnostic tests in this field can change patient outcomes and create market opportunities or risks for companies working on respiratory care; think of it as the 'engine shop' for the body’s air system.
nephrology medical
"tele-specialty coverage in cardiology, pulmonology, and nephrology, enabling"
Nephrology is the branch of medicine that diagnoses and treats kidney function and diseases, including conditions that affect the body’s natural ‘filtering’ system. For investors, nephrology matters because treatments, drugs, devices, and services for kidney disease represent a significant and growing market; outcomes, regulatory approvals, and changes in treatment standards can directly affect revenue, costs, and valuation for companies involved in healthcare, pharmaceuticals, and medical technology.
echocardiography medical
"completed the implementation of on-site echocardiography services and has partnered"
An echocardiography is a noninvasive test that uses sound waves to create moving images of the heart, showing its size, pumping strength and how the valves work—think of it as an ultrasound camera for the heart. Investors care because these images provide objective measures used to diagnose heart disease, guide treatment decisions, support clinical-trial endpoints and drive demand for medical devices and services, which affects revenue and reimbursement outlooks.

AI-generated analysis. Not financial advice.

WEST PALM BEACH, FL, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “Company”) today announced that its critical access-designated acute care hospital, Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), has expanded its clinical capabilities through the addition of inpatient tele-specialty services and cardiac diagnostics.

In partnership with Rural Physicians Group, Big South Fork Medical Center now provides inpatient tele-specialty coverage in cardiology, pulmonology, and nephrology, enabling more patients to receive specialty evaluation and treatment locally. The hospital has historically transferred out a number of patients each month that required these services. The hospital also recently completed the implementation of on-site echocardiography services and has partnered with CompuMed to provide professional interpretation of echo studies performed at the facility.

“These additions strengthen our ability to treat patients locally while maintaining appropriate clinical oversight,” said Cathal McGuckin, Interim Chief Executive Officer of Big South Fork Medical Center. “Tele-specialty support, combined with expanded diagnostics, improves care access and reduces unnecessary patient transfers.”

“This expansion reflects FOXO’s commitment to building a practical, technology-enabled care model to ensure long-term sustainability for our flagship rural hospital.,” noted Seamus Lagan, Chief Executive Officer of FOXO. “By strengthening clinical infrastructure and expanding access to specialty services, we believe our hospital can increase its net revenues and continue to effectively serve patients in their communities well into the future.”

About FOXO Technologies Inc. (“FOXO”)

FOXO owns and operates four key subsidiaries.

Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access designated (CAH) hospital in East Tennessee.

Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for medically supervised withdrawal treatment and residential treatment and outpatient services for MAT and OBOT programs.

Vector BioSource, Inc. is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries.

FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.

For more information about FOXO, visit www.foxotechnologies.com.

Forward-Looking Statements

This press release contains forward-looking statements that include words such as "expects," "anticipates," "believes," "intends," "plans," "projects," "estimates," "may," "will," "should," "could," or similar expressions, are forward-looking statements. These statements are not historical facts, including statements about FOXO’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

Sebastien Sainsbury
ssainsbury@foxotechnologies.com
(561) 485-0151


FAQ

What did FOXO (OTC: FOXO) announce about Big South Fork Medical Center on January 20, 2026?

FOXO announced expanded clinical capabilities: inpatient tele-specialty coverage in cardiology, pulmonology, and nephrology, plus on-site echocardiography with CompuMed interpretation.

Which specialties are covered by the new inpatient tele-specialty services at Big South Fork Medical Center?

The hospital added inpatient tele-specialty coverage in cardiology, pulmonology, and nephrology.

Who are FOXO's partners for the new clinical services at Big South Fork Medical Center?

FOXO partnered with Rural Physicians Group for tele-specialty coverage and with CompuMed for echocardiography interpretation.

How will the tele-specialty expansion affect patient transfers from Big South Fork Medical Center?

The company expects the tele-specialty services and expanded diagnostics to reduce unnecessary patient transfers by enabling more local specialty care.

Will FOXO's expansion at Big South Fork Medical Center immediately change company revenue or guidance?

The announcement states management believes net revenues can increase but does not provide specific financial figures or revised guidance.
FOXO TECHNOLOGIES

OTC:FOXO

FOXO Rankings

FOXO Latest News

FOXO Latest SEC Filings

FOXO Stock Data

1.04M
1.75B
0.21%
0.25%
4.32%
Health Information Services
Services-commercial Physical & Biological Research
Link
United States
WEST PALM BEACH